The majority of patients in whom this approach failed, did so because they had developed disease progression in the meantime. 4 With the advent of PVE, this period was dramatically shortened to 2 to 4 months, 5 and with concomitant portal vein ligature to about 4 weeks. 1 Other shortcomings included the insufficient hypertrophy of a putative remnant liver, preventing curative resection or, if performed, leading to postoperative failure due to "small for size" syndrome. 3 In Figure 1 , we show the development of the various types of staged hepatectomies.
The article in this issue of Annals of Surgery by Schnitzbauer and coworkers call out ref. 9 introduces a novel concept representing one of the most promising advances in oncological liver surgery so far. Contrary to many surgical innovations, this one was somehow developed by chance. In 2007, Dr Hans Schlitt from Regensburg, Germany, was planning an extended right hepatectomy in a patient with perihilar cholangiocarcinoma, but he realized intraoperatively that the future cholestatic liver remnant was too small to sustain the patient postoperatively. He took a good, but uncommon surgical decision, by performing only a selective hepatico-jejunostomy on the left biliary system. For the optimal positioning of the hepatico-jejunostomy, he had to divide the liver parenchyma along the falciform ligament, thereby completely devascularizing segment IV, that is, an in-situ split as performed for pediatric liver transplantation. Finally, he ligated the right portal vein to induce hypertrophy of segments II to III. Out of curiosity, he performed a CT scan on postoperative day 8 and, to his surprise, found that the left liver had grown enormously. He decided to proceed with the removal of the diseased liver. The patient, who had been at risk of liver failure a week prior, tolerated the removal just fine.
After this successful case, Dr Schlitt deliberately applied this approach in a patient with extensive colorectal liver metastases and in another patient with a large cholangiocarcinoma. The enthusiasm for this approach was then shared with other surgeons, mostly from Germany, who used it in highly select cases. The first formal report of this novel approach was offered, as a series of 3 cases, on a poster presented by Hauke Lang, from Mainz, Germany, during the ninth E-AHPBA meeting in Cape Town, South Africa, April 2011. 10 In the meantime, cases and technical aspects were also reported by the group from Buenos Aires, Argentina. 11, 12 Schnitzbauer et al describe here the initial experience with respect to 25 cases performed in 5 German centers and thereby introduce, for the first time, a new strategy to deal with extensive tumor load that could change the face of liver surgery for many reasons ( Figure 1) . First, the new strategy elegantly addresses the most feared complication following major hepatectomies: "postoperative liver failure." 1, 3 The diseased right hemiliver, left in place, acts as an auxiliary liver to assist the future liver remnant for the first and critical week after resection. The group from Buenos Aires, Argentina, assessed the uptake of 99mTc HIDA (dimethyl iminodiacetic acid), 11 and surprisingly, they found that the contralateral diseased liver remained functional and represented up to 60% of total liver function 6 days after the first surgery. In Zurich, indocyanide green testing was performed serially before and after the first and second surgery, showing that the metabolic capacity of the liver is mostly compromised after removal of the diseased lobe in the second step (unpublished data). Obviously, the "deportalized" but arterialized right hemiliver helps the patient get over the first week. A week later, it may then be removed with impunity, or if regeneration is not appropriate, the second step can be delayed.
Second, this new operation induces an amount of hypertrophy that is unparalleled by other techniques. Schnitzbauer et al report a 74% volume increase of the remnant liver in a mean of 9 days. We were able to confirm a consistent rapid increase in the size of the left liver within 1 week after the first surgery, and furthermore, we observed an even more dramatic increase in regeneration within a week after the removal of the diseased liver. In healthy livers, the maximum peak of regeneration is achieved at 2 weeks. 13 The current technique defies this classic concept. Schnitzbauer et al describe in one patient features of hyperplasia in the histological examination of the remnant liver at the time of the second operation. We observed features of hepatocyte apoptosis in the diseased liver, and enhanced markers of hepatocyte proliferation in the remnant liver. We must assume that the combination of portal vein ligation, with a large inflammatory injury, and the absence of cross portal circulation between the 2 parts of the liver, by completely transecting the parenchyma has a profound effect on liver regeneration. The precise mechanisms behind this spectacular regenerative response, however, still need to be explored.
The rapid regenerative response offers additional significant advantages. For example, tumor progression is unlikely during this short period. Some laboratory 14 and clinical 15 evidence exists, suggesting enhanced tumor progression in the remnant liver, after portal vein occlusion. There are also technical advantages, because of the fact that the earlier the definitive liver resection procedure is performed, the less demanding it will become. The rapid hypertrophy of the remnant liver enables the surgeons to proceed with the second surgery, before the development of disturbing adhesions, and may allow a faster recovery for the patient, with the possibility of restoring chemotherapy earlier.
Simultaneous colorectal and major liver resections are associated with higher morbidity and mortality rates in patients older than 65 years. 16 Many of these patients had extensive exposure to chemotherapy with associated liver damage. The current technique allows performing the colorectal resection simultaneously with the first step of the procedure, including the tumor cleaning of the future liver remnant, thus minimizing the risk of complications associated with postoperative liver failure. In most cases, the second hepatectomy has been a major challenge approached with earlier techniques of 2-stage hepatectomy, mostly related to the long interval between the 2 operations and the development of challenging adhesions. This initial series by Schnitzbauer et al, despite a shorter interval between the 2 operations, reports significant morbidity and 10% mortality (3/25). It is expected that increased experience with this procedure will lower the rate of complications.
Finally, laboratory tests that estimate liver reserve before liver resection may become obsolete as the "deportalized" auxiliary liver can be left in place during the critical regenerative phase of the future remnant liver; just like rubber boots in the operating room became unnecessary with less blood loss.
The novelty of this technique is the in-situ split, as labeled by the authors, leading to liver partition, which we believe, will likewise become standard in many specialized centers in the near future. Therefore, it is important to generate a self-explanatory and wellaccepted denomination for this procedure. We propose the acronym "ALPPS" for Associating Liver Partition and Portal vein Ligation for Staged hepatectomy.
Some aspects of this demanding procedure require further discussion. The authors report waiting times between both surgeries of up to 28 days. However, in our opinion, the second step can usually be completed by postoperative day 7. Criteria other than volume would be welcome, especially to assess the function of the putative remnant liver. This might be particularly relevant in patients presenting steatosis, steatohepatitis, sinusoidal obstructive syndrome, or fibrosis.
The raw surface of the diseased liver, being partially ischemic after the first step, might be associated with a higher risk of biliary leaks. With this in mind, the Buenos Aires group has wrapped the whole diseased-ischemic liver in a hermetic plastic bag with a drain inside it. This potentially prevents a chole-peritoneum and facilitates the second procedure, because of a reduction of adhesions. Also, the same group routinely places a catheter in the cystic duct, and performs a hydraulic test, to detect any biliary leak on the surface of the remnant liver. In both Buenos Aires and Zurich, we routinely perform a portal pedicle lymphadenectomy, not only for oncological reasons but also for a better identification of the hilar structures and portal vein ligation. To facilitate the identification of hepatic veins, hepatic artery and portal pedicle at the time of the second operation, we routinely encircle them with a strong black silk. During the second procedure, we usually use vascular staplers to easily and rapidly complete the liver resection.
In their work, the German surgeons selected patients with a tumor-free left lateral section (segments II-III) for this approach. In contrast, we also removed tumors from the putative remnant liver, without the concern of ending this procedure with a small-for-size syndrome, because the contra lateral diseased lobe will act as an auxiliary liver. 11 This technique should probably not be restricted for right trisectionectomy (segments IV-VIII ± segment I), but also for left trisectionectomy (segments I-V + segment VIII) and other atypical resections.
These complex procedures must be undertaken exclusively by experienced HPB surgeons in a high-volume center, and by means of a multidisciplinary team effort. The management of these patients during the postoperative course of both surgical procedures is crucial to achieve success. Further development of this procedure will require consensus regarding anesthesiology recovery, hemodynamic management, antibiotics, early enteral/parenteral nutrition, and other issues to achieve the best results.
This novel strategy raises hope to cure patients during a single hospital stay from severe liver disease that might otherwise be judged unresectable by means of a 2-stage surgical approach. This technique readdresses the current management of locally advanced liver malignancies and opens a new chapter in the history of liver surgery. The question of how well this new approach works in cirrhotic patients or after heavy chemotherapy has yet to be determined. Thanks to Dr Schlitt's finding, many liver surgeons will be busy with this question for a long time.
Considering the 5 stages of the new surgical procedures "IDEAL" (Innovation, Development, Exploration, Assessment, and Long term), as proposed by the Balliol group 17,18 the current multicenter pilot study fits with the first-stage "Innovation," in which it involved highly selected patients and very few surgeons, and in which proper ethical approval is often problematic. This article clearly brings this new approach to the next step of "Development" involving more surgeons, more patients, a learning curve, and possible future randomized controlled trials, for example by comparing the ALPPS with earlier strategies, omitting the in-situ part.
